Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
5
×
boston top stories
boulder/denver blog main
boulder/denver top stories
deals
5
×
detroit blog main
detroit top stories
eli lilly
5
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
5
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
cancer
alzheimer's disease
cancer immunotherapy
johnson & johnson
medicare
pfizer
takeda pharmaceutical
abbvie
aduro biotech
What
bio
5
×
roundup
drug
alzheimer’s
companies
new
pharmaceutical
price
typically
acquisitions
approval
bails
biggest
biogen’s
biopharmaceutical
brand
bridgebio
build
buy
capital
car
ceo
company’s
congress
convo
daniel
debut
democrats
develop
different
divided
drugs
dyne’s
earlier
elections
emerges
fail
failures
fallout
firm
Language
unset
Current search:
bio
×
deals
×
novartis
×
" eli lilly "
×
" boston blog main "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel